迈威生物(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688062 迈威生物

已收盘 11-19 15:00:01

{"stockData":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物","latestPrice":22.75,"timestamp":1731999601000,"preClose":23.57,"halted":0,"volume":5133435,"delay":0,"floatShares":204000000,"shares":400000000,"eps":-2.6883,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.82,"latestTime":"11-19 15:00:01","open":23.69,"high":24.07,"low":21.93,"amount":117000000,"amplitude":0.0908,"askPrice":22.79,"askSize":26,"bidPrice":22.75,"bidSize":179,"shortable":0,"etf":0,"ttmEps":-2.6883,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732066200000},"adr":0,"adjPreClose":23.57,"symbolType":"stock_kcb","openAndCloseTimeList":[[1731979800000,1731987000000],[1731992400000,1731999600000]],"highLimit":25.93,"lowLimit":21.21,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":399600000,"pbRate":4.74,"roa":"--","roe":"--","epsLYR":-2.64,"committee":-0.037037,"marketValue":9091000000,"floatMarketCap":4645000000,"peRate":-8.462598,"changeRate":-0.0348,"turnoverRate":0.0251,"status":1,"afterMarket":{"amount":0,"volume":0,"close":22.75,"buyVolume":0,"sellVolume":0,"time":1732001594464,"indexStatus":"已收盘 11-19 15:30:00","preClose":23.57}},"requestUrl":"/m/hq/s/688062","defaultTab":"news","newsList":[{"id":"2484954877","title":"迈威生物-U跌5% 近半年2券商增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2484954877","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484954877?lang=zh_cn&edition=full","pubTime":"2024-11-19 11:12","pubTimestamp":1731985975,"startTime":"0","endTime":"0","summary":"11月19日，迈威生物-U股价大幅下跌，截至11点12分，迈威生物-U下跌5.05%，报22.38元/股，成交6190万元，换手率1.32%，振幅7.25%。资金动向截止发稿，迈威生物-U获得主力净流出467万元，其中超大单流出537万元，大单流入71万元。主营业务及业绩迈威生物-U公司主营业务为治疗用生物制品的研发、生产与销售。最新财报显示，今年三季报，迈威生物-U实现营业收入1.41亿元，同比增长41.79%，净利润为-6.94亿元，同比减少3.09%，基本每股收益为-1.74元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119111301a24489db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119111301a24489db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2483841567","title":"迈威生物-U11月14日获主力加仓2842万元 环比增加341.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483841567","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483841567?lang=zh_cn&edition=full","pubTime":"2024-11-14 15:22","pubTimestamp":1731568942,"startTime":"0","endTime":"0","summary":"11月14日, 迈威生物-U股价跌1.80%，报收24.55元，成交金额1.42亿元，换手率2.79%，振幅4.48%，量比1.04。迈威生物-U今日主力资金净流入2842万元，连续6日净流入，上一交易日主力净流入643万元，今日环比增加341.99%。近一年数据显示，该股主力连续6日净流入后，次日上涨概率为33.33%，平均涨幅为3.90%。该股近5个交易日上涨5.77%，主力资金累计净流入5296万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入858万元，其中净流入天数为11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114155138abc02cfc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114155138abc02cfc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2482961718","title":"迈威生物-U大幅上涨 生物医药产业蓬勃发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2482961718","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482961718?lang=zh_cn&edition=full","pubTime":"2024-11-12 09:58","pubTimestamp":1731376701,"startTime":"0","endTime":"0","summary":"11月12日，迈威生物-U股价大幅上涨，截至09点58分，迈威生物-U上涨5.01%，报25.17元/股，成交5659万元，换手率1.13%。资金动向截止发稿，迈威生物-U获得主力净流入1105万元，其中超大单流入451万元，大单流入654万元。主营业务及业绩迈威生物-U公司主营业务为治疗用生物制品的研发、生产与销售。最新财报显示，今年三季报，迈威生物-U实现营业收入1.41亿元，同比增长41.79%，净利润为-6.94亿元，同比减少3.09%，基本每股收益为-1.74元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112095853a22e215a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112095853a22e215a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","399441","161726","688062"],"gpt_icon":0},{"id":"2482226849","title":"迈威生物-U大幅上涨 上海医保签订采购意向书","url":"https://stock-news.laohu8.com/highlight/detail?id=2482226849","media":"智选洞察","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482226849?lang=zh_cn&edition=full","pubTime":"2024-11-11 13:23","pubTimestamp":1731302611,"startTime":"0","endTime":"0","summary":"11月11日，迈威生物-U股价大幅上涨，截至13点23分，迈威生物-U上涨5.01%，报24.10元/股，成交9029万元，换手率1.90%。礼来、强生等外资医药企业分别与上药控股、上海市药事所签订了采购意向书，但具体的产品尚未确定。主营业务及业绩迈威生物-U公司主营业务为治疗用生物制品的研发、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111132508abb4c931&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111132508abb4c931&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2480089523","title":"迈威生物：收入稳步放量 创新品种持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2480089523","media":"国联证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480089523?lang=zh_cn&edition=full","pubTime":"2024-11-04 00:00","pubTimestamp":1730649600,"startTime":"0","endTime":"0","summary":"商业化产品陆续放量公司已上市品种3 个，单季度来看，迈利舒（骨松）实现销售收入2356.24 万元，截至报告期末，累计完成30 省招标挂网，累计准入医院1336 家，覆盖药店2632家。君迈康仍计入君实口径，累计准入医院270 家，覆盖药店1370 家。创新品种稳步推进临床2024Q3，9MW2821 获准启动2 项Ⅲ期临床研究，主要针对宫颈癌、联合PD-1 单抗治疗1L 尿路上皮癌，目前均处于入组阶段。维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110418462395bdc87a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110418462395bdc87a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2479774566","title":"迈威生物(688062)9月30日股东户数1.38万户，较上期增加1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479774566","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479774566?lang=zh_cn&edition=full","pubTime":"2024-10-31 17:10","pubTimestamp":1730365835,"startTime":"0","endTime":"0","summary":"证券之星消息，近日迈威生物披露，截至2024年9月30日公司股东户数为1.38万户，较6月30日增加201.0户，增幅为1.48%。在化学制药行业个股中，迈威生物股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.1万户。从股价来看，2024年6月30日至2024年9月30日，迈威生物区间跌幅为4.53%，在此期间股东户数增加201.0户，增幅为1.48%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100033745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2479370807","title":"图解迈威生物三季报：第三季度单季净利润同比增4.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479370807","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479370807?lang=zh_cn&edition=full","pubTime":"2024-10-31 01:28","pubTimestamp":1730309293,"startTime":"0","endTime":"0","summary":"证券之星消息，迈威生物2024年三季报显示，公司主营收入1.41亿元，同比上升41.79%；归母净利润-6.94亿元，同比下降3.09%；扣非净利润-7.15亿元，同比下降5.45%；其中2024年第三季度，公司单季度主营收入2556.79万元，同比上升167.73%；单季度归母净利润-2.49亿元，同比上升4.1%；单季度扣非净利润-2.54亿元，同比上升3.15%；负债率57.64%，投资收益-271.64万元，财务费用2274.08万元，毛利率92.46%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100002484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062"],"gpt_icon":0},{"id":"2479487162","title":"迈威生物-U大跌5.08% 2家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2479487162","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479487162?lang=zh_cn&edition=full","pubTime":"2024-10-30 13:21","pubTimestamp":1730265661,"startTime":"0","endTime":"0","summary":"10月30日，迈威生物-U股价大幅下跌，截至13点21分，迈威生物-U下跌5.08%，报22.78元/股，创近1个月新低，成交9985万元，换手率2.08%，振幅4.87%。此外，数据统计显示，近半年内2家券商给予增持建议，6家券商给予买入建议。资金动向截止发稿，迈威生物-U获得主力净流出2067万元，其中超大单流出2684万元，大单流入618万元。主营业务及业绩迈威生物-U公司主营业务为治疗用生物制品的研发、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030132114a1f7d760&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030132114a1f7d760&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2477841980","title":"科技打头阵，如何低门槛布局科创板？","url":"https://stock-news.laohu8.com/highlight/detail?id=2477841980","media":"博时基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477841980?lang=zh_cn&edition=full","pubTime":"2024-10-22 07:55","pubTimestamp":1729554913,"startTime":"0","endTime":"0","summary":"多家A股半导体行业上市公司披露了2024年前三季度业绩预告，业绩普遍预喜。科创100指数ETF只需要开通上海证券交易所基金账户，且满足交易风险评级要求，即可参与交易。ETF基金的过往业绩及其净值高低并不预示其未来业绩表现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022075245971a1755&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022075245971a1755&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688327","688276","688062","688172","688005","688548","688106","688200","688347","688153","688433","688484","688789","688248","688409","688608","688029","688063","688088","688232","688266","688498","688556","688400","688336","688146","688048","688110","688778","688050","688567","688278","688520","688739","688578","688439","688612","688568","688390","688352","688582","688037","688052","688100","688032","688166","688007","688772","588030","688702","688055","688027","688798","688017","688575","688617","688083","688213","688526","688147","688387","688443","688549","688333","688001","688425","688192","159982","688639","688208","688139","688516","688343","688322","688006","688289","688097","688177","688700","688066","688019","688348","688366","688361","688235","000698","688281","688717","688016","688141","688107","688161","688408","688105","688331","688432","688318","688686","688690","688002","688536","688779","688326","688198"],"gpt_icon":0},{"id":"2476444466","title":"迈威生物-U大幅上涨 股东减持计划密集发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2476444466","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476444466?lang=zh_cn&edition=full","pubTime":"2024-10-18 13:04","pubTimestamp":1729227858,"startTime":"0","endTime":"0","summary":"10月18日，迈威生物-U股价大幅上涨，截至13点04分，迈威生物-U上涨5.06%，报24.69元/股，成交6447万元，换手率1.32%。此外，还有27家企业股东、高管抛出减持计划。资金动向截止发稿，迈威生物-U获得主力净流出26万元，其中超大单流出128万元，大单流入103万元。主营业务及业绩迈威生物-U公司主营业务为治疗用生物制品的研发、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018130602a1e1979d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018130602a1e1979d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2474506054","title":"10月11日迈威生物-U跌7.37%，汇添富医疗服务灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2474506054","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474506054?lang=zh_cn&edition=full","pubTime":"2024-10-11 16:14","pubTimestamp":1728634487,"startTime":"0","endTime":"0","summary":"证券之星消息，10月11日迈威生物-U跌7.37%，收盘报25.12元，换手率2.29%，成交量4.68万手，成交额1.21亿元。根据2024基金半年报公募基金重仓股数据，重仓该股的公募基金共53家，其中持有数量最多的公募基金为汇添富医疗服务灵活配置混合A。汇添富医疗服务灵活配置混合A目前规模为27.25亿元，最新净值1.332，较上一交易日下跌0.15%，近一年上涨12.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101100023446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2474032483","title":"迈威生物-U大跌5.86% 3家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2474032483","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474032483?lang=zh_cn&edition=full","pubTime":"2024-10-11 13:49","pubTimestamp":1728625790,"startTime":"0","endTime":"0","summary":"10月11日，迈威生物-U股价大幅下跌，截至13点49分，迈威生物-U下跌5.86%，报25.53元/股，成交7967万元，换手率1.48%，振幅7.04%。资金动向截止发稿，迈威生物-U获得主力净流出104万元，其中超大单流入9万元，大单流出112万元。主营业务及业绩迈威生物-U公司主营业务为治疗用生物制品的研发、生产与销售。最新财报显示，今年中报，迈威生物-U实现营业收入1.16亿元，同比增长28.42%，净利润为-4.45亿元，同比减少7.61%，基本每股收益为-1.11元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241011135030a1dfe487&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241011135030a1dfe487&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2474734413","title":"迈威生物-U大幅上涨 广东生物医药产业高质量发展行动方案发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2474734413","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474734413?lang=zh_cn&edition=full","pubTime":"2024-10-10 09:31","pubTimestamp":1728523869,"startTime":"0","endTime":"0","summary":"10月10日，迈威生物-U股价大幅上涨，截至09点31分，迈威生物-U上涨6.39%，报29.79元/股，成交145万元，换手率0.02%，振幅5.50%。消息解读广东省人民政府办公厅印发《关于进一步推动广东生物医药产业高质量发展的行动方案》。《行动方案》提出，力争到2027年，广东省生物医药与健康产业集群规模超万亿元，规上医药工业规模超5000亿元，助力广东省高质量建设生物医药强省。主营业务及业绩迈威生物-U公司主营业务为治疗用生物制品的研发、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241010100105a1df9093&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241010100105a1df9093&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["161726","399441","BK0239","688062"],"gpt_icon":0},{"id":"2474726579","title":"迈威生物-U大跌5.03% 获融资净买入984万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2474726579","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474726579?lang=zh_cn&edition=full","pubTime":"2024-10-09 09:31","pubTimestamp":1728437484,"startTime":"0","endTime":"0","summary":"10月09日，迈威生物-U股价大幅下跌，截至09点31分，迈威生物-U下跌5.03%，报28.71元/股，失守30元整数关口，成交312万元，换手率0.05%，振幅3.94%。资金动向截止发稿，迈威生物-U获得主力净流出31万元，其中超大单流出232万元，大单流入201万元。融资融券方面，迈威生物-U10月08日获得融资净买入984万元，当日该股融资余额为1.15亿元，当较前一日增加9.39%，实现2连增；该股融券余额为93万元，融券余量为3.26万股，比上日增加37.03%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241009123054ab68b4d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241009123054ab68b4d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2473443654","title":"10月8日迈威生物-U涨9.41%，汇添富医疗服务灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2473443654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473443654?lang=zh_cn&edition=full","pubTime":"2024-10-08 17:04","pubTimestamp":1728378253,"startTime":"0","endTime":"0","summary":"证券之星消息，10月8日迈威生物-U涨9.41%创60日新高，收盘报30.23元，换手率5.2%，成交量10.62万手，成交额3.22亿元。根据2024基金半年报公募基金重仓股数据，重仓该股的公募基金共53家，其中持有数量最多的公募基金为汇添富医疗服务灵活配置混合A。汇添富医疗服务灵活配置混合A目前规模为27.25亿元，最新净值1.324，较上一交易日上涨10.61%，近一年上涨10.43%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100800024963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2473466292","title":"迈威生物-U创3个月新高 3家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2473466292","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473466292?lang=zh_cn&edition=full","pubTime":"2024-10-08 09:30","pubTimestamp":1728351002,"startTime":"0","endTime":"0","summary":"10月08日，迈威生物-U股价大幅上涨，截至09点30分，迈威生物-U上涨12.23%，报31.01元/股，创近3个月新高，突破30元整数关口，成交559万元，换手率0.08%，振幅7.20%。此外，数据统计显示，近半年内3家券商给予增持建议，11家券商给予买入建议。资金动向截止发稿，迈威生物-U获得主力净流出3215万元，其中超大单流出1297万元，大单流出1916万元。主营业务及业绩迈威生物-U公司主营业务为治疗用生物制品的研发、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241008103223ab684977&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241008103223ab684977&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2473515334","title":"创新医药行业周报：看好医药中的高弹性成长板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2473515334","media":"财通证券股份有...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473515334?lang=zh_cn&edition=full","pubTime":"2024-10-08 00:00","pubTimestamp":1728316800,"startTime":"0","endTime":"0","summary":"看好医药板块在本轮牛市中能成为一大主线。本轮美联储开启新一轮降息周期后，叠加国家宏观经济政策加强政策刺激，医药板块整体情绪反弹较为明显。持续看好本轮牛市行情中的医药板块，建议关注创新药、CXO 与科研服务、出海链以及低估值公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410080837469596ad80&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410080837469596ad80&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688117","159938","688293","688278","BK0239","688139","688177","01801","688046","600276","688428","603127","09969","06127","688131","688062","688076","09926","03347","688321","688578"],"gpt_icon":0},{"id":"2472836498","title":"【机构调研记录】财通基金调研迈威生物、腾景科技等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2472836498","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472836498?lang=zh_cn&edition=full","pubTime":"2024-10-01 08:02","pubTimestamp":1727740952,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及9月30日披露的机构调研信息，财通基金近期对3家上市公司进行了调研，相关名单如下：1）迈威生物 个股亮点：公司9MW2821是公司研发的一款靶向Nectin-4的ADC型创新药。旗下最近一年表现最佳的公募基金产品为财通福佑定开混合发起，最新单位净值为1.55，近一年增长62.35%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100100010310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","688195","BK0214","BK0239"],"gpt_icon":0},{"id":"2472436498","title":"【机构调研记录】德邦基金调研迈威生物、腾景科技等4只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2472436498","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472436498?lang=zh_cn&edition=full","pubTime":"2024-10-01 08:02","pubTimestamp":1727740923,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及9月30日披露的机构调研信息，德邦基金近期对4家上市公司进行了调研，相关名单如下：1）迈威生物 个股亮点：公司9MW2821是公司研发的一款靶向Nectin-4的ADC型创新药。4）金开新能 个股亮点：主营业务为新能源电力的开发、投资、建设和运营，目前主要包括光伏发电和风力发电两个板块。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100100010260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","688195","BK0214","BK0239"],"gpt_icon":0},{"id":"2472981364","title":"【机构调研记录】富荣基金调研华侨城A、迈威生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2472981364","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472981364?lang=zh_cn&edition=full","pubTime":"2024-10-01 08:01","pubTimestamp":1727740915,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及9月30日披露的机构调研信息，富荣基金近期对2家上市公司进行了调研，相关名单如下：1）华侨城A 个股亮点：公司双主业发展：文化旅游和房地产。富荣基金成立于2016年，截至目前，资产管理规模175.97亿元，排名121/207；资产管理规模101.95亿元，排名119/207；管理公募基金数35只，排名118/207；旗下公募基金经理8人，排名125/207。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100100010250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0157","BK0183","BK0239","BK0010","000069","BK0188","688062","BK0273","BK0028","BK0178","BK0196","BK0187","BK0012"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-01-18","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路230号2幢105室","stockEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":-0.0534},{"period":"3month","weight":0.0551},{"period":"6month","weight":-0.2907},{"period":"1year","weight":-0.1293},{"period":"ytd","weight":-0.279}],"companyName":"迈威(上海)生物科技股份有限公司","boardCode":"AI0027","perCapita":"14789股","boardName":"医药制造业","registeredCapital":"39960万元","compareEarnings":[{"period":"1week","weight":-0.0421},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.1595},{"period":"6month","weight":0.0523},{"period":"1year","weight":0.0882},{"period":"ytd","weight":0.1173}],"survey":"　　迈威(上海)生物科技股份有限公司是一家创新型生物制药企业，主营业务为治疗用生物制品的研发、生产与销售，主要产品为抗体药物。截至本招股说明书签署日，新增授权专利4项，新增专利申请48项，独立承担1项国家“重大新药创制”重大科技专项，独立承担2项国家重点研发计划。","serverTime":1732001600810,"listedPrice":34.8,"stockholders":"13805人(较上一季度增加1.48%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物,688062,迈威生物股票,迈威生物股票老虎,迈威生物股票老虎国际,迈威生物行情,迈威生物股票行情,迈威生物股价,迈威生物股市,迈威生物股票价格,迈威生物股票交易,迈威生物股票购买,迈威生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}